ImmunityBio reported durable complete responses in early data from an allogeneic, off‑the‑shelf CD19 CAR‑NK program combined with rituximab in patients with Waldenström’s non‑Hodgkin lymphoma. The small Phase 1 dataset showed complete responses sustained through seven and 15 months in two patients, with disease control in those who had failed standard therapies and without use of lymphodepleting chemotherapy. Dosing was done in the outpatient setting and responses were reported as durable; the company highlighted the regimen’s tolerability. CAR‑NK cells are natural killer cells engineered to express a chimeric antigen receptor targeting CD19; unlike autologous CAR‑T, off‑the‑shelf CAR‑NK can be administered without individualized manufacturing. ImmunityBio’s result signals potential for allogeneic cell therapies in B‑cell malignancies that avoid lymphodepletion, but the dataset is early and limited to a handful of patients. Investors reacted quickly to the data, reflecting heightened market interest in off‑the‑shelf cellular platforms.